{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:52:45Z","timestamp":1780789965018,"version":"3.54.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100021566","name":"Fundaci\u00f3n Isabel Gemio","doi-asserted-by":"publisher","award":["2018\/0200"],"award-info":[{"award-number":["2018\/0200"]}],"id":[{"id":"10.13039\/501100021566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021566","name":"Fundaci\u00f3n Isabel Gemio","doi-asserted-by":"publisher","award":["2018\/0200"],"award-info":[{"award-number":["2018\/0200"]}],"id":[{"id":"10.13039\/501100021566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM19\/00104"],"award-info":[{"award-number":["CM19\/00104"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00114"],"award-info":[{"award-number":["PI20\/00114"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP22\/00028"],"award-info":[{"award-number":["CP22\/00028"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00333"],"award-info":[{"award-number":["PI15\/00333"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM19\/00104"],"award-info":[{"award-number":["CM19\/00104"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014849","name":"Conselleria de Cultura, Educaci\u00f3n y Ciencia, Generalitat Valenciana","doi-asserted-by":"publisher","award":["APOSTD\/2021\/212"],"award-info":[{"award-number":["APOSTD\/2021\/212"]}],"id":[{"id":"10.13039\/501100014849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FPU21\/00912"],"award-info":[{"award-number":["FPU21\/00912"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biobizkaia Health Research Institute","award":["BC\/I\/DIV\/19\/001"],"award-info":[{"award-number":["BC\/I\/DIV\/19\/001"]}]},{"name":"Basque Government, Spain","award":["2016111029"],"award-info":[{"award-number":["2016111029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Skeletal Muscle"],"DOI":"10.1186\/s13395-024-00353-3","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T09:01:56Z","timestamp":1727773316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model"],"prefix":"10.1186","volume":"14","author":[{"given":"Javier","family":"Poyatos-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Soblechero-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Liquori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"L\u00f3pez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Maestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Gonz\u00e1lez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael P.","family":"V\u00e1zquez-Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Muelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ohana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Arechavala-Gomeza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"V\u00edlchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,1]]},"reference":[{"key":"353_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nrm2024","volume":"7","author":"KE Davies","year":"2006","unstructured":"Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol. 2006;7:762\u201373.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"353_CR2","doi-asserted-by":"crossref","unstructured":"Rando TA. The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve. 2001;24:1575\u201394.","DOI":"10.1002\/mus.1192"},{"key":"353_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","volume":"1","author":"AEH Emery","year":"1991","unstructured":"Emery AEH. Population frequencies of inherited neuromuscular diseases-A world survey. Neuromuscul Disord. 1991;1:19\u201329.","journal-title":"Neuromuscul Disord"},{"key":"353_CR4","doi-asserted-by":"crossref","unstructured":"Emery AEH, Muntoni F, Quinlivan RCM. Duchenne muscular dystrophy. OUP Oxford; 2015.","DOI":"10.1093\/med\/9780199681488.001.0001"},{"key":"353_CR5","unstructured":"Darras BT, Urion DK, Ghosh PS. Dystrophinopathies. GeneReviews\u00ae [Internet]. 2022 [cited 2022 Jun 22];35. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1119\/"},{"key":"353_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/0140-6736(91)92671-N","volume":"337","author":"KMD Bushby","year":"1991","unstructured":"Bushby KMD, Thambyayah M, Gardner-Medwin D. Prevalence and incidence of Becker muscular dystrophy. Lancet. 1991;337:1022\u20134.","journal-title":"Lancet"},{"key":"353_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/mus.21193","volume":"39","author":"V Ferreiro","year":"2009","unstructured":"Ferreiro V, Giliberto F, Mu\u00f1iz GMN, Francipane L, Marzese DM, Mampel A, et al. Asymptomatic Becker muscular dystrophy in a family with a multiexon deletion. Muscle Nerve. 2009;39:239\u201343.","journal-title":"Muscle Nerve"},{"key":"353_CR8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/jnnp.2004.037325","volume":"76","author":"MB Sanchez-Arjona","year":"2005","unstructured":"Sanchez-Arjona MB. Spanish family with myalgia and cramps syndrome. J Neurol Neurosurg Psychiatry. 2005;76:286\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"353_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/ph8020303","volume":"8","author":"A Nakamura","year":"2015","unstructured":"Nakamura A. X-Linked dilated cardiomyopathy: a cardiospecific phenotype of Dystrophinopathy. Pharmaceuticals. 2015;8:303\u201320.","journal-title":"Pharmaceuticals"},{"key":"353_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1212\/WNL.46.2.461","volume":"46","author":"KN North","year":"1996","unstructured":"North KN, Miller G, Iannaccone ST, Clemens PR, Chad DA, Bella I, et al. Cognitive dysfunction as the major presenting feature of Becker\u2019s muscular dystrophy. Neurology. 1996;46:461\u20134.","journal-title":"Neurology"},{"key":"353_CR11","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/hmg\/ddu537","volume":"24","author":"A Nicolas","year":"2015","unstructured":"Nicolas A, Ragu\u00e9n\u00e8s-Nicol C, Ben Yaou R, Ameziane-Le Hir S, Ch\u00e9ron A, Vi\u00e9 V, et al. Becker muscular dystrophy severity is linked to the structure of dystrophin. Hum Mol Genet. 2015;24:1267\u201379.","journal-title":"Hum Mol Genet"},{"key":"353_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/jcm8050649","volume":"8","author":"L Bello","year":"2019","unstructured":"Bello L, Pegoraro E. The Usual suspects: genes for inflammation, fibrosis, regeneration, and muscle strength modify Duchenne muscular dystrophy. J Clin Med. 2019;8:649.","journal-title":"J Clin Med"},{"key":"353_CR13","doi-asserted-by":"crossref","unstructured":"Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nature Reviews Neurology. 2019;15:373\u201386.","DOI":"10.1038\/s41582-019-0203-3"},{"key":"353_CR14","doi-asserted-by":"crossref","unstructured":"Tang A, Yokota T. Duchenne muscular dystrophy: promising early-stage clinical trials to watch. Expert Opin Investig Drugs. 2024;33:201\u201317.","DOI":"10.1080\/13543784.2024.2313105"},{"key":"353_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2174\/156652312800840621","volume":"12","author":"V Arechavala-Gomeza","year":"2012","unstructured":"Arechavala-Gomeza V, Anthony K, Morgan J, Muntoni F. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: Progress and challenges. Curr Gene Ther. 2012;12:152\u201360.","journal-title":"Curr Gene Ther"},{"key":"353_CR16","doi-asserted-by":"crossref","unstructured":"Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RMC et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (1979). 2016;351:403\u20137.","DOI":"10.1126\/science.aad5143"},{"key":"353_CR17","doi-asserted-by":"crossref","unstructured":"Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science (1979). 2016;351:400\u20133.","DOI":"10.1126\/science.aad5725"},{"key":"353_CR18","doi-asserted-by":"crossref","unstructured":"Amoasii L, Hildyard JCW, Li H, Sanchez-Ortiz E, Mireault A, Caballero D et al. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science (1979). 2018;362:86\u201391.","DOI":"10.1126\/science.aau1549"},{"key":"353_CR19","doi-asserted-by":"crossref","unstructured":"Tabebordbar M, Cheng J, Wagers AJ. Therapeutic Gene Editing in Muscles and Muscle Stem Cells. Research and Perspectives in Neurosciences. 2017;103\u201323.","DOI":"10.1007\/978-3-319-60192-2_10"},{"key":"353_CR20","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther. 2018;26:2337\u201356.","journal-title":"Mol Ther"},{"key":"353_CR21","doi-asserted-by":"crossref","unstructured":"Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med. 2021;13:e13243.","DOI":"10.15252\/emmm.202013243"},{"key":"353_CR22","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1093\/brain\/awr291","volume":"134","author":"K Anthony","year":"2011","unstructured":"Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain. 2011;134:3544\u201356.","journal-title":"Brain"},{"key":"353_CR23","doi-asserted-by":"crossref","unstructured":"Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, Janghra N et al. Biochemical Characterization of Patients With In-Frame or Out-of-Frame DMD Deletions Pertinent to Exon 44 or 45 Skipping. JAMA Neurol. 2014;71:32.","DOI":"10.1001\/jamaneurol.2013.4908"},{"key":"353_CR24","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2017","unstructured":"Nakamura A, Shiba N, Miyazaki D, Nishizawa H, Inaba Y, Fueki N, et al. Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet. 2017;62:459\u201363.","journal-title":"J Hum Genet"},{"key":"353_CR25","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/humu.21114","volume":"30","author":"KM Flanigan","year":"2009","unstructured":"Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT, et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat. 2009;30:1657\u201366.","journal-title":"Hum Mutat"},{"key":"353_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/humu.20428","volume":"28","author":"C B\u00e9roud","year":"2007","unstructured":"B\u00e9roud C, Tuffery-Giraud S, Matsuo M, Hamroun D, Humbertclaude V, Monnier N, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat. 2007;28:196\u2013202.","journal-title":"Hum Mutat"},{"key":"353_CR27","doi-asserted-by":"crossref","unstructured":"Poyatos-Garc\u00eda J, Mart\u00ed P, Liquori A, Muelas N, Pitarch I, Martinez\u2010Dolz L et al. Dystrophinopathy Phenotypes and Modifying Factors in\u2009DMD \u2009Exon 45\u201355 Deletion. Ann Neurol. 2022;92:793\u2013806.","DOI":"10.1002\/ana.26461"},{"key":"353_CR28","doi-asserted-by":"crossref","unstructured":"Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T et al. Bodywide skipping of exons 45\u201355 in dystrophic mdx52 mice by systemic antisense delivery. Proceedings of the National Academy of Sciences. 2012;109:13763\u20138.","DOI":"10.1073\/pnas.1204638109"},{"key":"353_CR29","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B, Panesar D, Touznik A, Nagata T, et al. Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45\u201355 with a cocktail of vivo-morpholinos in Mdx52 mice. Mol Ther Nucleic Acids. 2015;4:e225.","journal-title":"Mol Ther Nucleic Acids"},{"key":"353_CR30","doi-asserted-by":"crossref","unstructured":"Lee J, Echigoya Y, Duddy W, Saito T, Aoki Y, Takeda ichi et al. Antisense PMO cocktails effectively skip dystrophin exons 45\u201355 in myotubes transdifferentiated from DMD patient fibroblasts. 2018;13(5):e0197084.","DOI":"10.1371\/journal.pone.0197084"},{"key":"353_CR31","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.ymthe.2019.07.012","volume":"27","author":"Y Echigoya","year":"2019","unstructured":"Echigoya Y, Lim KRQ, Melo D, Bao B, Trieu N, Mizobe Y, et al. Exons 45\u201355 skipping using mutation-tailored cocktails of antisense morpholinos in the DMD Gene. Mol Ther. 2019;27:2005\u201317.","journal-title":"Mol Ther"},{"key":"353_CR32","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.1038\/ncomms7244","volume":"6","author":"DG Ousterout","year":"2015","unstructured":"Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA. Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun. 2015;6:6244.","journal-title":"Nat Commun"},{"key":"353_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-Derived muscle cells. Cell Stem Cell. 2016;18:533\u201340.","journal-title":"Cell Stem Cell"},{"key":"353_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3233\/JND-170218","volume":"4","author":"CS Young","year":"2017","unstructured":"Young CS, Mokhonova E, Quinonez M, Pyle AD, Spencer MJ. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne muscular dystrophy and application of a CRISPR\/Cas9 gene editing therapy. J Neuromuscul Dis. 2017;4:139\u201345.","journal-title":"J Neuromuscul Dis"},{"key":"353_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13395-016-0115-5","volume":"6","author":"M Thorley","year":"2016","unstructured":"Thorley M, Duguez S, Mazza EMC, Valsoni S, Bigot A, Mamchaoui K, et al. Skeletal muscle characteristics are preserved in hTERT\/cdk4 human myogenic cell lines. Skelet Muscle. 2016;6:1\u201312.","journal-title":"Skelet Muscle"},{"key":"353_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2044-5040-1-34","volume":"1","author":"K Mamchaoui","year":"2011","unstructured":"Mamchaoui K, Trollet C, Bigot A, Negroni E, Chaouch S, Wolff A, et al. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle. 2011;1:34.","journal-title":"Skelet Muscle"},{"key":"353_CR37","doi-asserted-by":"crossref","unstructured":"Soblechero-Mart\u00edn P, Albiasu-Arteta E, Anton-Martinez A, de la Puente-Ovejero L, Garcia-Jimenez I, Gonz\u00e1lez-Iglesias G et al. Duchenne muscular dystrophy cell culture models created by CRISPR\/Cas9 gene editing and their application in drug screening. Sci Rep. 2021;11:18188.","DOI":"10.1038\/s41598-021-97730-5"},{"key":"353_CR38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.omtn.2021.08.010","volume":"25","author":"M Sabater-Arcis","year":"2021","unstructured":"Sabater-Arcis M, Bargiela A, Moreno N, Poyatos-Garcia J, Vilchez JJ, Artero R. Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression. Mol Ther Nucleic Acids. 2021;25:652\u201367.","journal-title":"Mol Ther Nucleic Acids"},{"key":"353_CR39","doi-asserted-by":"crossref","unstructured":"Poyatos-Garc\u00eda J, Bl\u00e1zquez-Bernal \u00c1, Selva-Gim\u00e9nez M, Bargiela A, Espinosa-Espinosa J, V\u00e1zquez-Manrique RP et al. CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2. Mol Ther Nucleic Acids. 2023;31:324\u201338.","DOI":"10.1016\/j.omtn.2023.01.004"},{"key":"353_CR40","first-page":"11","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protocols. 2013;8:11.","journal-title":"Nat Protocols 2013"},{"key":"353_CR41","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.omtn.2017.08.003","volume":"8","author":"C Fuster-Garc\u00eda","year":"2017","unstructured":"Fuster-Garc\u00eda C, Garc\u00eda-Garc\u00eda G, Gonz\u00e1lez-Romero E, Jaijo T, Sequedo MD, Ayuso C, et al. USH2A gene editing using the CRISPR System. Mol Ther Nucleic Acids. 2017;8:529\u201341.","journal-title":"Mol Ther Nucleic Acids"},{"key":"353_CR42","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae S, Park J, Kim J-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics. 2014;30:1473\u20135.","journal-title":"Bioinformatics"},{"key":"353_CR43","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Mart\u00ednez A, Soblechero-Mart\u00edn P, Arechavala-Gomeza V. Evaluation of Exon Skipping and Dystrophin Restoration in In Vitro Models of Duchenne Muscular Dystrophy. Arechavala-Gomeza V, Garanto A, editors. Methods Mol Biol. 2022;2434:217\u201333.","DOI":"10.1007\/978-1-0716-2010-6_14"},{"key":"353_CR44","doi-asserted-by":"crossref","unstructured":"Ruiz-Del-Yerro E, Garcia-Jimenez I, Mamchaoui K, Arechavala-Gomeza V. Myoblots: dystrophin quantification by in-cell western assay for a streamlined development of Duchenne muscular dystrophy (DMD) treatments. Neuropathol Appl Neurobiol. 2018;44:463\u201373.","DOI":"10.1111\/nan.12448"},{"key":"353_CR45","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1212\/WNL.0000000000001025","volume":"83","author":"K Anthony","year":"2014","unstructured":"Anthony K, Arechavala-Gomeza V, Taylor LE, Vulin A, Kaminoh Y, Torelli S, et al. Dystrophin quantification: Biological and translational research implications. Neurology. 2014;83:2062\u20139.","journal-title":"Neurology"},{"key":"353_CR46","doi-asserted-by":"publisher","first-page":"W267","DOI":"10.1093\/nar\/gkw407","volume":"44","author":"JC Oliveros","year":"2016","unstructured":"Oliveros JC, Franch M, Tabas-Madrid D, San-Le\u00f3n D, Montoliu L, Cubas P, et al. Breaking-Cas\u2014interactive design of guide RNAs for CRISPR-Cas experiments for ENSEMBL genomes. Nucleic Acids Res. 2016;44:W267\u201371.","journal-title":"Nucleic Acids Res"},{"key":"353_CR47","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement K, Rees H, Canver MC, Gehrke JM, Farouni R, Hsu JY, et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol. 2019;37:224\u20136.","journal-title":"Nat Biotechnol"},{"key":"353_CR48","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1242\/dev.151035","volume":"144","author":"J Chal","year":"2017","unstructured":"Chal J, Pourqui\u00e9 O. Making muscle: skeletal myogenesis in vivo and in vitro. Development. 2017;144:2104\u201322.","journal-title":"Development"},{"key":"353_CR49","doi-asserted-by":"crossref","unstructured":"Schmidt M, Sch\u00fcler SC, H\u00fcttner SS, von Eyss B, von Maltzahn J. Adult stem cells at work: regenerating skeletal muscle. Cellular and Molecular Life Sciences. 2019;76:2559\u201370.","DOI":"10.1007\/s00018-019-03093-6"},{"key":"353_CR50","doi-asserted-by":"crossref","unstructured":"Zhang H, Shang R, Bi P. Feedback regulation of Notch signaling and myogenesis connected by MyoD\u2013Dll1 axis. PLoS Genet. 2021;17:e1009729.","DOI":"10.1371\/journal.pgen.1009729"},{"key":"353_CR51","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.24222","volume":"76","author":"N Doorenweerd","year":"2014","unstructured":"Doorenweerd N, Straathof CS, Dumas EM, Spitali P, Ginjaar IB, Wokke BH, et al. Reduced cerebral gray matter and altered white matter in boys with Duchenne muscular dystrophy. Ann Neurol. 2014;76:403\u201311.","journal-title":"Ann Neurol"},{"key":"353_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/WNL.55.4.559","volume":"55","author":"G Felisari","year":"2000","unstructured":"Felisari G, Boneschi FM, Bardoni A, Sironi M, Comi GP, Robotti M, et al. Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy. Neurology. 2000;55:559\u201364.","journal-title":"Neurology"},{"key":"353_CR53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/biomedicines9020219","volume":"9","author":"E Gargaun","year":"2021","unstructured":"Gargaun E, Falcone S, Sol\u00e9 G, Durigneux J, Urtizberea A, Cuisset JM, et al. The lncRNA 44s2 study applicability to the design of 45\u201355 exon skipping therapeutic strategy for DMD. Biomedicines. 2021;9:219.","journal-title":"Biomedicines"},{"key":"353_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/hmg\/4.3.329","volume":"4","author":"HGW Lidov","year":"1995","unstructured":"Lidov HGW, Selig S, Kunkel LM. Dp140: a novel 140\u00a0kDa CNS transcript from the dystrophin locus. Hum Mol Genet. 1995;4:329\u201335.","journal-title":"Hum Mol Genet"},{"key":"353_CR55","doi-asserted-by":"publisher","first-page":"e45328","DOI":"10.1371\/journal.pone.0045328","volume":"7","author":"M Bovolenta","year":"2012","unstructured":"Bovolenta M, Erriquez D, Valli E, Brioschi S, Scotton C, Neri M, et al. The DMD Locus Harbours multiple long non-coding RNAs which orchestrate and Control Transcription of Muscle Dystrophin mRNA isoforms. PLoS ONE. 2012;7:e45328.","journal-title":"PLoS ONE"},{"key":"353_CR56","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajhg.2015.11.012","volume":"98","author":"D Wojtal","year":"2016","unstructured":"Wojtal D, Kemaladewi DU, Malam Z, Abdullah S, Wong TWY, Hyatt E, et al. Spell checking Nature: versatility of CRISPR\/Cas9 for developing treatments for inherited disorders. Am J Hum Genet. 2016;98:90\u2013101.","journal-title":"Am J Hum Genet"},{"key":"353_CR57","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7150\/thno.47007","volume":"11","author":"S Zhang","year":"2021","unstructured":"Zhang S, Shen J, Li D, Cheng Y. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing. Theranostics. 2021;11:614\u201348.","journal-title":"Theranostics"},{"key":"353_CR58","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/gr.171322.113","volume":"24","author":"S Kim","year":"2014","unstructured":"Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24:1012\u20139.","journal-title":"Genome Res"},{"key":"353_CR59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","volume":"171","author":"L Li","year":"2018","unstructured":"Li L, Hu S, Chen X. Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities. Biomaterials. 2018;171:207\u201318.","journal-title":"Biomaterials"},{"key":"353_CR60","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","volume":"342","author":"EA Taha","year":"2022","unstructured":"Taha EA, Lee J, Hotta A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. J Controlled Release. 2022;342:345\u201361.","journal-title":"J Controlled Release"},{"key":"353_CR61","doi-asserted-by":"crossref","unstructured":"Mcinerney P, Adams P, Hadi MZ. Error Rate Comparison during Polymerase Chain Reaction by DNA Polymerase. 2014;204:287430.","DOI":"10.1155\/2014\/287430"},{"key":"353_CR62","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00439-017-1820-9","volume":"136","author":"S Tuffery-Giraud","year":"2017","unstructured":"Tuffery-Giraud S, Miro J, Koenig M, Claustres M. Normal and altered pre-mRNA processing in the DMD gene. Hum Genet. 2017;136:1155\u201372.","journal-title":"Hum Genet"},{"key":"353_CR63","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2990.2009.01056.x","volume":"36","author":"V Arechavala-Gomeza","year":"2009","unstructured":"Arechavala-Gomeza V, Kinali M, Feng L, Brown SC, Sewry C, Morgan JE, et al. Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol Appl Neurobiol. 2009;36:265\u201374.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"353_CR64","doi-asserted-by":"crossref","unstructured":"van den Bergen JC, Wokke BH, Janson AA, van Duinen SG, Hulsker MA, Ginjaar HB et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J Neurol Neurosurg Psychiatry. 2014;85:747\u201353.","DOI":"10.1136\/jnnp-2013-306350"}],"container-title":["Skeletal Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-024-00353-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13395-024-00353-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13395-024-00353-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T09:08:42Z","timestamp":1727773722000},"score":1,"resource":{"primary":{"URL":"https:\/\/skeletalmusclejournal.biomedcentral.com\/articles\/10.1186\/s13395-024-00353-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["353"],"URL":"https:\/\/doi.org\/10.1186\/s13395-024-00353-3","relation":{},"ISSN":["2044-5040"],"issn-type":[{"value":"2044-5040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]},"assertion":[{"value":"7 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the experiments were approved by the Health Research Institute La Fe Ethics\u2019 Committee (ID: 2018\/0200).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}